Kura Oncology (KURA) Announces Clinical Hold on Phase 1b Study of KO-539
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Kura Oncology (KURA) PT Lowered to $32 at H.C. Wainwright
November 24, 2021 10:20 AM ESTH.C. Wainwright analyst Joseph Pantginis lowered the price target on Kura Oncology (NASDAQ: KURA) to $32.00 (from $43.00) while maintaining a Buy rating.
The analyst commented, "This morning, Kura announced the FDA has placed a partial clinical hold on the KOMET-001 Phase 1b study evaluating KO-539 in patients with relapsed or refractory acute myeloid leukemia (AML). The hold was put in place... More
